Published in Ann Allergy on October 01, 1979
Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol (1999) 2.23
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab Dispos (2000) 1.67
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos (1997) 1.30
Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res (2000) 1.00
Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol (1999) 0.95
Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. Ann Oncol (2001) 0.91
Shelf-lives and factors affecting the stability of morphine sulphate and meperidine (pethidine) hydrochloride in plastic syringes for use in patient-controlled analgesic devices. J Clin Pharm Ther (1994) 0.90
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol (1999) 0.89
Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. Eur J Clin Pharmacol (1987) 0.88
Analysis of 5'-deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatography. J Chromatogr (1985) 0.86
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies. Cancer Chemother Pharmacol (2008) 0.84
Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans. Cancer Res (1998) 0.82
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. J Clin Oncol (1998) 0.80
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study. Cancer Chemother Pharmacol (1998) 0.79
Fully automated high-performance liquid chromatographic method for the determination of carzelesin (U-80,244) and metabolites (U-76,073 and U-76,074) in human plasma. J Chromatogr (1994) 0.79
Effects of injection site and flow rate on the distribution of injected solutions in an extracorporeal membrane oxygenation circuit. Am J Hosp Pharm (1993) 0.78
Alternative dosing schedules for irinotecan. Oncology (Williston Park) (1998) 0.77
Evaluation of the pharmacokinetic interaction between cimetidine or famotidine and cyclosporine in healthy men. Ann Pharmacother (1995) 0.76
Effect of an enteral nutrient formula on sustained-release theophylline absorption. Ther Drug Monit (1989) 0.75
Effect of sucralfate on theophylline absorption in healthy volunteers. Clin Pharm (1988) 0.75
Comparison of harmonic mean versus arithmetic mean clearance values. J Pharm Sci (1986) 0.75